carotuximab

AssetAlso ENV-105, c-SN6j, DE-122, TRC-105

Monoclonal antibody targeting endoglin (CD105) to address drug resistance in cancer

Stage: Phase 2
Modality: Antibody
Target: ENG; 1
Indication: 0
Trials: 1
Developer

Indications

1

Metastatic castration-resistant prostate cancer
Phase 2, businesswire.com, 6 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners1
Evidence for its targets1
Competitors1

Every asset’s record: target, stage, trials and the evidence behind it.